UPDATE: Canaccord Genuity Starts Guardant Health (GH) at Buy

(updated to add analyst comment)

Canaccord Genuity analyst Mark Massaro initiates coverage on Guardant Health (NASDAQ: GH) with a Buy rating and a price target of $90.00.

The analyst comments "We view Guardant Health as the leader in liquid biopsy cancer testing, laser focused on building on its mass of data, proving the clinical and economic utility of its tests, to (1) help cancer patients live longer (on the right targeted therapies) for therapy selection; 2) perform recurrence monitoring of the ~15M American cancer survivors today; and later (3) screening ~35M "higher-risk" Americans for cancer with a simple blood test, across a range of cancers, at a combined."

For an analyst ratings summary and ratings history on Guardant Health click here. For more ratings news on Guardant Health click here.

Shares of Guardant Health closed at $75.00 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Libra Energy Materials options two Quebec lithium projects near Cisco
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald